1. Home
  2. EUDA vs LPTX Comparison

EUDA vs LPTX Comparison

Compare EUDA & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EUDA
  • LPTX
  • Stock Information
  • Founded
  • EUDA 2021
  • LPTX 2011
  • Country
  • EUDA Singapore
  • LPTX United States
  • Employees
  • EUDA N/A
  • LPTX N/A
  • Industry
  • EUDA Blank Checks
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EUDA Finance
  • LPTX Health Care
  • Exchange
  • EUDA Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • EUDA 139.3M
  • LPTX 119.6M
  • IPO Year
  • EUDA N/A
  • LPTX N/A
  • Fundamental
  • Price
  • EUDA $3.68
  • LPTX $0.31
  • Analyst Decision
  • EUDA
  • LPTX Buy
  • Analyst Count
  • EUDA 0
  • LPTX 2
  • Target Price
  • EUDA N/A
  • LPTX $8.00
  • AVG Volume (30 Days)
  • EUDA 105.3K
  • LPTX 5.8M
  • Earning Date
  • EUDA 01-01-0001
  • LPTX 03-26-2025
  • Dividend Yield
  • EUDA N/A
  • LPTX N/A
  • EPS Growth
  • EUDA N/A
  • LPTX N/A
  • EPS
  • EUDA N/A
  • LPTX N/A
  • Revenue
  • EUDA $3,811,496.00
  • LPTX N/A
  • Revenue This Year
  • EUDA $66.63
  • LPTX N/A
  • Revenue Next Year
  • EUDA $119.95
  • LPTX N/A
  • P/E Ratio
  • EUDA N/A
  • LPTX N/A
  • Revenue Growth
  • EUDA N/A
  • LPTX N/A
  • 52 Week Low
  • EUDA $1.64
  • LPTX $0.28
  • 52 Week High
  • EUDA $6.30
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • EUDA 43.29
  • LPTX 25.59
  • Support Level
  • EUDA $3.64
  • LPTX $0.41
  • Resistance Level
  • EUDA $4.04
  • LPTX $0.65
  • Average True Range (ATR)
  • EUDA 0.22
  • LPTX 0.05
  • MACD
  • EUDA -0.01
  • LPTX 0.03
  • Stochastic Oscillator
  • EUDA 14.06
  • LPTX 6.78

About EUDA EUDA Health Holdings Limited

EUDA Health Holdings Ltd is a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem aimed at making healthcare affordable and accessible, The company's proprietary unified AI platform quickly assesses a patient's medical history, triages a condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. The company caters to all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. The company operates in two segments namely Medical services and property management services, out of which the company derives its maximum revenue from Medical services.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: